{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056882","form_type":"8-K","ticker":null,"cik":"0001260990","company_name":"Oncternal Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.641935+00:00","generated_at":"2026-06-02T05:00:14.379143+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncternal Q1 net loss $8.4M; ONCT-534 cohort fully enrolled; cash runway into Q1 2025","bullets":["Net loss $8.4M ($2.83 per share); grant revenue $0.6M; total operating expenses $9.3M including $1.4M stock-based compensation.","Cash, cash equivalents & short-term investments $27.0M as of March 31, 2024; no debt; projected runway into Q1 2025.","Phase 1/2 ONCT-534 for advanced prostate cancer: fourth cohort (300 mg/day) fully enrolled; initial data expected late Q2 2024.","Phase 1/2 ONCT-808 (ROR1 CAR T) for aggressive B-cell lymphoma open and enrolling; clinical update expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056882","json":"https://secwatch.observer/filing/0000950170-24-056882.json","markdown":"https://secwatch.observer/filing/0000950170-24-056882.md","text":"https://secwatch.observer/filing/0000950170-24-056882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/0000950170-24-056882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/onct-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:00:14.379143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d4508167c78f1287e8559c01088d1ca57df140","claim":"Oncternal Therapeutics, Inc. reported for the quarter ended March 31, 2024 results: revenue $0.6 million, net income Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share, EPS $2.83 per share, basic and diluted.","evidence_excerpt":"T cell therapy ‒ Clinical data update in mid-2024 ‒ Additional clinical data readouts in the fourth quarter of 2024 First Quarter 2024 Financial Results Our grant revenue was $0.6 million for the first quarter ended March 31, 2024. Our total operating expenses for the first quarter ended March 31, 2024 were $9.3 million, including $1.4 million in non-cash","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1260990/000095017024056882/0000950170-24-056882-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.6 million"},{"label":"Net income","value":"Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share"},{"label":"EPS","value":"$2.83 per share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}